Contact

Research

0
Scientific Abstracts/
Presentations
0
Peer Reviewed
Publications
0 +
Patients
Studied

Outcomes from AeroPace Clinical Studies Showed

Using AeroPace Therapy Compared to Standard of Care, More patients weaned:

37 %
Reduced risk of remaining on mechanical ventilation at 30 days by up to 37%
60 %
Reduced risk for reintubation at 30 days by up to 60%
3 Days
Faster weaning by nearly 3 days

The AeroPace System is indicated is to improve weaning success – increase weaning, reduce ventilator days, and reduce reintubation – in patients ages 18 years or older on mechanical ventilation ≥ 96 hours and who have not weaned. It is the first device of this kind approved by FDA.

The AeroPace System is contraindicated in patients with active implanted cardiac pacemakers, defibrillators, or other implantable electronics within proximity to the device. The AeroPace System has not been clinically evaluated for safety with implantable devices.

Published Research

Linkedin Twitter Youtube

© 2024 Lungpacer Medical Inc. ®

The AeroPace System is approved by the United States Food and Drug Administration to improve weaning success in adult patients on MV at least 96 hours and who have not weaned. The AeroPace System is not approved in any other country.

CAUTION: The AeroNova System is limited by Federal law (United States) to investigational use. Used exclusively for clinical investigations.

Lungpacer® Medical, AeroPace® System and AeroNova® System are registered trademarks of Lungpacer Medical.